Reduction of soluble Aβ and Tau, but not soluble Aβ alone, ameliorates cognitive decline in transgenic mice with plaques and tangles

被引:242
作者
Oddo, Salvatore
Vasilevko, Vitaly
Caccamo, Antonella
Kitazawa, Masashi
Cribbs, David H.
LaFerla, Frank M.
机构
[1] Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA
[2] Univ Calif Irvine, Inst Brain Aging & Dementia, Irvine, CA 92697 USA
关键词
TG2576 MOUSE MODEL; ALZHEIMERS-DISEASE; MEMORY LOSS; IN-VIVO; IMMUNIZATION; PATHOLOGY; PEPTIDE; IMMUNOTHERAPY; DEFICITS; NEURODEGENERATION;
D O I
10.1074/jbc.M608485200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Increasing evidence points to soluble assemblies of aggregating proteins as a major mediator of neuronal and synaptic dysfunction. In Alzheimer disease ( AD), soluble amyloid-beta (A beta) appears to be a key factor in inducing synaptic and cognitive abnormalities. Here we report the novel finding that soluble tau also plays a role in the cognitive decline in the presence of concomitant A beta pathology. We describe improved cognitive function following a reduction in both soluble A beta and tau levels after active or passive immunization in advanced aged 3xTg-AD mice that contain both amyloid plaques and neurofibrillary tangles (NFTs). Notably, reducing soluble A beta alone did not improve the cognitive phenotype in mice with plaques and NFTs. Our results show that A beta immunotherapy reduces soluble tau and ameliorates behavioral deficit in old transgenic mice.
引用
收藏
页码:39413 / 39423
页数:11
相关论文
共 46 条
[1]   DISTRIBUTION OF ALZHEIMER-TYPE PATHOLOGICAL-CHANGES IN NONDEMENTED ELDERLY INDIVIDUALS MATCHES THE PATTERN IN ALZHEIMERS-DISEASE [J].
ARRIAGADA, PV ;
MARZLOFF, K ;
HYMAN, BT .
NEUROLOGY, 1992, 42 (09) :1681-1688
[2]   Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].
Bard, F ;
Cannon, C ;
Barbour, R ;
Burke, RL ;
Games, D ;
Grajeda, H ;
Guido, T ;
Hu, K ;
Huang, JP ;
Johnson-Wood, K ;
Khan, K ;
Kholodenko, D ;
Lee, M ;
Lieberburg, I ;
Motter, R ;
Nguyen, M ;
Soriano, F ;
Vasquez, N ;
Weiss, K ;
Welch, B ;
Seubert, P ;
Schenk, D ;
Yednock, T .
NATURE MEDICINE, 2000, 6 (08) :916-919
[3]   Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice [J].
Billings, LM ;
Oddo, S ;
Green, KN ;
McGaugh, JL ;
LaFerla, FM .
NEURON, 2005, 45 (05) :675-688
[4]   The cytoskeleton in neurodegenerative diseases [J].
Cairns, NJ ;
Lee, VMY ;
Trojanowski, JQ .
JOURNAL OF PATHOLOGY, 2004, 204 (04) :438-449
[5]   Nerve inflammation halts trial for Alzheimer's drug [J].
Check, E .
NATURE, 2002, 415 (6871) :462-462
[6]   Natural oligomers of the amyloid-protein specifically disrupt cognitive function [J].
Cleary, JP ;
Walsh, DM ;
Hofmeister, JJ ;
Shankar, GM ;
Kuskowski, MA ;
Selkoe, DJ ;
Ashe, KH .
NATURE NEUROSCIENCE, 2005, 8 (01) :79-84
[7]   Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with β-amyloid [J].
Cribbs, DH ;
Ghochikyan, A ;
Vasilevko, V ;
Tran, M ;
Petrushina, I ;
Sadzikava, N ;
Babikyan, D ;
Kesslak, P ;
Kieber-Emmons, T ;
Cotman, CW ;
Agadjanyan, MG .
INTERNATIONAL IMMUNOLOGY, 2003, 15 (04) :505-514
[8]   Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition [J].
Das, P ;
Murphy, MP ;
Younkin, LH ;
Younkin, SG ;
Golde, TE .
NEUROBIOLOGY OF AGING, 2001, 22 (05) :721-727
[9]   Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease [J].
DeMattos, RB ;
Bales, KR ;
Cummins, DJ ;
Dodart, JC ;
Paul, SM ;
Holtzman, DM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (15) :8850-8855
[10]   Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model [J].
Dodart, JC ;
Bales, KR ;
Gannon, KS ;
Greene, SJ ;
DeMattos, RB ;
Mathis, C ;
DeLong, CA ;
Wu, S ;
Wu, X ;
Holtzman, DM ;
Paul, SM .
NATURE NEUROSCIENCE, 2002, 5 (05) :452-457